| Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1) a randomised, controlled, phase 3 trial |
51 |
| Management of IgG4-related disease |
16 |
| Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial |
9 |
| Risk factors for dislocation after primary total hip replacement: a systematic review and meta-analysis of 125 studies involving approximately five million hip replacements |
8 |
| Probiotic treatment using a mix of three Lactobacillus strains for lumbar spine bone loss in postmenopausal women: a randomised, double-blind, placebo-controlled, multicentre trial |
7 |
| IgG4-related disease in the Japanese population: a genome-wide association study |
7 |
| Symptom-based stratification of patients with primary Sjogren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials |
6 |
| Definitions of remission in systemic lupus erythematosus: a post-hoc analysis of two randomised clinical trials |
6 |
| The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program |
6 |
| Comparative efficacy and safety of treatments for secondary Raynaud's phenomenon: a systematic review and network meta-analysis of randomised trials |
5 |
| Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study |
5 |
| Routine repeated echocardiographic monitoring of fetuses exposed to maternal anti-SSA antibodies: time to question the dogma |
5 |
| Evaluation of remission definitions for systemic lupus erythematosus: a prospective cohort study |
4 |
| Opioid use, postoperative complications, and implant survival after unicompartmental versus total knee replacement: a population-based network study |
4 |
| Methotrexate withdrawal in patients with rheumatoid arthritis who achieve low disease activity with tofacitinib modified-release 11 mg once daily plus methotrexate (ORAL Shift): a randomised, phase 3b/ non-inferiority trial |
3 |
| The nosology of systemic sclerosis: how lessons from the past offer new challenges in reframing an idiopathic rheumatological disorder |
2 |
| Making the right thing the easy thing to do: strategies to improve outcomes in gout |
1 |
| Ultra-low doses of rituximab for continued treatment of rheumatoid arthritis (REDO study): a randomised controlled non-inferiority trial |
1 |
| IBI a biosimilar to adalimumab, for the treatment of patients with ankylosing spondylitis in China: a randomised, double-blind, phase 3 equivalence trial |
1 |
| Precision medicine in psoriatic arthritis: how should we select targeted therapies? |
1 |
| Association of social support with patient-reported outcomes after joint replacement: a systematic review and meta-analysis |
0 |
| Disease heterogeneity in antineutrophil cytoplasmic antibody-associated vasculitis: implications for therapeutic approaches |
0 |
